Cargando…

Serum YKL-40 and colorectal cancer

YKL-40 is a mammalian member of the chitinase protein family. Although the function of YKL-40 is unknown, the pattern of its expression suggests a function in remodelling or degradation of extracellular matrix. High serum YKL-40 has been found in patients with recurrent breast cancer and has been re...

Descripción completa

Detalles Bibliográficos
Autores principales: Cintin, C, Johansen, J S, Christensen, I J, Price, P A, Sørensen, S, Nielsen, H J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362720/
https://www.ncbi.nlm.nih.gov/pubmed/10188896
http://dx.doi.org/10.1038/sj.bjc.6690238
_version_ 1782153524189069312
author Cintin, C
Johansen, J S
Christensen, I J
Price, P A
Sørensen, S
Nielsen, H J
author_facet Cintin, C
Johansen, J S
Christensen, I J
Price, P A
Sørensen, S
Nielsen, H J
author_sort Cintin, C
collection PubMed
description YKL-40 is a mammalian member of the chitinase protein family. Although the function of YKL-40 is unknown, the pattern of its expression suggests a function in remodelling or degradation of extracellular matrix. High serum YKL-40 has been found in patients with recurrent breast cancer and has been related to short survival. In the present study we analysed YKL-40 in preoperative sera from patients with colorectal cancer and evaluated its relation to survival. Serum YKL-40 was determined by RIA in 603 patients. Survival after operation was registered, and median follow-up time was 61 months. Three hundred and forty patients died. Sixteen per cent of the patients with Dukes' A, 26% with Dukes' B, 19% with Dukes' C and 39% with Dukes' D had high serum YKL-40 levels (adjusted for age). Analysis of serum YKL-40 as a continuous variable showed an association between increased serum YKL-40 and short survival (P < 0.0001). Patients with high preoperative serum YKL-40 concentration had significantly shorter survival than patients with normal YKL-40 (HR = 1.7; 95% CI: 1.3–2.1, P < 0.0001). Multivariate Cox analysis including serum YKL-40, serum CEA, Dukes' stage, age and gender showed that high YKL-40 was an independent prognostic variable for short survival (HR = 1.4; 95% CI: 1.1–1.8, P = 0.007). These results suggest that YKL-40 may play an important role in tumour invasion. © 1999 Cancer Research Campaign
format Text
id pubmed-2362720
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23627202009-09-10 Serum YKL-40 and colorectal cancer Cintin, C Johansen, J S Christensen, I J Price, P A Sørensen, S Nielsen, H J Br J Cancer Regular Article YKL-40 is a mammalian member of the chitinase protein family. Although the function of YKL-40 is unknown, the pattern of its expression suggests a function in remodelling or degradation of extracellular matrix. High serum YKL-40 has been found in patients with recurrent breast cancer and has been related to short survival. In the present study we analysed YKL-40 in preoperative sera from patients with colorectal cancer and evaluated its relation to survival. Serum YKL-40 was determined by RIA in 603 patients. Survival after operation was registered, and median follow-up time was 61 months. Three hundred and forty patients died. Sixteen per cent of the patients with Dukes' A, 26% with Dukes' B, 19% with Dukes' C and 39% with Dukes' D had high serum YKL-40 levels (adjusted for age). Analysis of serum YKL-40 as a continuous variable showed an association between increased serum YKL-40 and short survival (P < 0.0001). Patients with high preoperative serum YKL-40 concentration had significantly shorter survival than patients with normal YKL-40 (HR = 1.7; 95% CI: 1.3–2.1, P < 0.0001). Multivariate Cox analysis including serum YKL-40, serum CEA, Dukes' stage, age and gender showed that high YKL-40 was an independent prognostic variable for short survival (HR = 1.4; 95% CI: 1.1–1.8, P = 0.007). These results suggest that YKL-40 may play an important role in tumour invasion. © 1999 Cancer Research Campaign Nature Publishing Group 1999-03 /pmc/articles/PMC2362720/ /pubmed/10188896 http://dx.doi.org/10.1038/sj.bjc.6690238 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Cintin, C
Johansen, J S
Christensen, I J
Price, P A
Sørensen, S
Nielsen, H J
Serum YKL-40 and colorectal cancer
title Serum YKL-40 and colorectal cancer
title_full Serum YKL-40 and colorectal cancer
title_fullStr Serum YKL-40 and colorectal cancer
title_full_unstemmed Serum YKL-40 and colorectal cancer
title_short Serum YKL-40 and colorectal cancer
title_sort serum ykl-40 and colorectal cancer
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362720/
https://www.ncbi.nlm.nih.gov/pubmed/10188896
http://dx.doi.org/10.1038/sj.bjc.6690238
work_keys_str_mv AT cintinc serumykl40andcolorectalcancer
AT johansenjs serumykl40andcolorectalcancer
AT christensenij serumykl40andcolorectalcancer
AT pricepa serumykl40andcolorectalcancer
AT sørensens serumykl40andcolorectalcancer
AT nielsenhj serumykl40andcolorectalcancer